Literature DB >> 15670720

Elongation of very long-chain fatty acids is enhanced in X-linked adrenoleukodystrophy.

Stephan Kemp1, Fredoen Valianpour, Simone Denis, Rob Ofman, Robert-Jan Sanders, Petra Mooyer, Peter G Barth, Ronald J A Wanders.   

Abstract

X-linked adrenoleukodystrophy (X-ALD) is a progressive neurodegenerative disorder characterized by the accumulation of saturated and mono-unsaturated very long-chain fatty acids (VLCFA) and reduced peroxisomal VLCFA beta-oxidation activity. In this study, we investigated the role of VLCFA biosynthesis in X-ALD fibroblasts. Our data demonstrate that elongation of both saturated and mono-unsaturated VLCFAs is enhanced in fibroblasts from patients with peroxisomal beta-oxidation defects including X-ALD, and peroxisome biogenesis disorders. These data indicate that enhanced VLCFA elongation is a general phenomenon associated with an impairment in peroxisomal beta-oxidation, and not specific for X-ALD alone. Analysis of plasma samples from patients with X-ALD and different peroxisomal beta-oxidation deficiencies revealed increased concentrations of VLCFAs up to 32 carbons. We infer that enhanced elongation does not result from impaired peroxisomal beta-oxidation alone, but is due to the additional effect of unchecked chain elongation. We demonstrate that elongated VLCFAs are incorporated into complex lipids. The role of chain elongation was also studied retrospectively in samples from patients with X-ALD previously treated with "Lorenzo's oil." We found that the decrease in plasma C26:0 previously found is offset by the increase of mono-unsaturated VLCFAs, not measured previously during the trial. We conclude that evaluation of treatment protocols for disorders of peroxisomal beta-oxidation making use of plasma samples should include the measurement of saturated and unsaturated VLCFAs of chain lengths above 26 carbon atoms. We also conclude that chain elongation offers an interesting target to be studied as a possible mode of treatment for X-ALD and other peroxisomal beta-oxidation disorders.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15670720     DOI: 10.1016/j.ymgme.2004.09.015

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  30 in total

1.  ABCD1 deletion-induced mitochondrial dysfunction is corrected by SAHA: implication for adrenoleukodystrophy.

Authors:  Mauhamad Baarine; Craig Beeson; Avtar Singh; Inderjit Singh
Journal:  J Neurochem       Date:  2015-01-13       Impact factor: 5.372

2.  Brain microsomal fatty acid elongation is increased in abcd1-deficient mouse during active myelination phase.

Authors:  Masashi Morita; Misato Kawamichi; Yusuke Shimura; Kosuke Kawaguchi; Shiro Watanabe; Tsuneo Imanaka
Journal:  Metab Brain Dis       Date:  2015-06-25       Impact factor: 3.584

Review 3.  X-linked adrenoleukodystrophy: pathogenesis and treatment.

Authors:  Marc Engelen; Stephan Kemp; Bwee-Tien Poll-The
Journal:  Curr Neurol Neurosci Rep       Date:  2014-10       Impact factor: 5.081

Review 4.  Biochemistry and genetics of inherited disorders of peroxisomal fatty acid metabolism.

Authors:  Paul P Van Veldhoven
Journal:  J Lipid Res       Date:  2010-06-17       Impact factor: 5.922

5.  Metabolic rerouting via SCD1 induction impacts X-linked adrenoleukodystrophy.

Authors:  Quentin Raas; Malu-Clair van de Beek; Sonja Forss-Petter; Inge Me Dijkstra; Abigail Deschiffart; Briana C Freshner; Tamara J Stevenson; Yorrick Rj Jaspers; Liselotte Nagtzaam; Ronald Ja Wanders; Michel van Weeghel; Joo-Yeon Engelen-Lee; Marc Engelen; Florian Eichler; Johannes Berger; Joshua L Bonkowsky; Stephan Kemp
Journal:  J Clin Invest       Date:  2021-04-15       Impact factor: 14.808

6.  Identification of atypical ether-linked glycerophospholipid species in macrophages by mass spectrometry.

Authors:  Pavlina T Ivanova; Stephen B Milne; H Alex Brown
Journal:  J Lipid Res       Date:  2009-11-30       Impact factor: 5.922

Review 7.  "Lorenzo's oil" therapy for X-linked adrenoleukodystrophy: rationale and current assessment of efficacy.

Authors:  Hugo W Moser; Ann B Moser; Kim Hollandsworth; N Hong Brereton; Gerald V Raymond
Journal:  J Mol Neurosci       Date:  2007-09       Impact factor: 3.444

8.  Fast diffusion of very long chain saturated fatty acids across a bilayer membrane and their rapid extraction by cyclodextrins: implications for adrenoleukodystrophy.

Authors:  Biju K Pillai; Ravi Jasuja; Jeffrey R Simard; James A Hamilton
Journal:  J Biol Chem       Date:  2009-09-28       Impact factor: 5.157

9.  MicroRNA Profiling Identifies miR-196a as Differentially Expressed in Childhood Adrenoleukodystrophy and Adult Adrenomyeloneuropathy.

Authors:  Navjot Shah; Inderjit Singh
Journal:  Mol Neurobiol       Date:  2016-02-03       Impact factor: 5.590

10.  A model-based approach to assess the exposure-response relationship of Lorenzo's oil in adrenoleukodystrophy.

Authors:  Mariam A Ahmed; Reena V Kartha; Richard C Brundage; James Cloyd; Cynthia Basu; Bradley P Carlin; Richard O Jones; Ann B Moser; Ali Fatemi; Gerald V Raymond
Journal:  Br J Clin Pharmacol       Date:  2016-04-03       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.